Development of Styryl‐Modified 3,4‐Dihydropyrimidin‐2(1 H )‐ones as Potential Antitumor Agents
ChemMedChem · 14.04.2026 · 21 (7)
DOI: 10.1002/cmdc.202501073 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 07.04.2026. Verfasst von Konstantinos Panagoulias und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyrimidines, Pyrimidinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Research.
Abstract (Originalsprache)
Monastrol, a DHPM‐based Eg5 inhibitor with well‐known antiproliferative activity but limited therapeutic potential due to poor solubility and low bioavailability, was selected as the lead compound for the design of styryl‐modified 3,4‐dihydropyrimidin‐2(1 H )‐ones with an improved pharmaceutical profile. Twelve derivatives ( 10–21 ) were synthesized via the Biginelli reaction and evaluated for cytotoxicity in HeLa and MCF‐7 cells. Styryl derivatives 16 and 17 emerged as the most active. In HeLa cells, derivatives 17 (IC50 = 1.3 µM) and 16 (IC50 = 3.7 µM) were approximately 85‐fold and 30‐fold more potent than monastrol (IC50 = 111 µM), respectively. In MCF‐7 cells, derivatives 16 and 17 displayed 18‐ to 20‐fold higher potency than monastrol, respectively. Biological results also indicate that styryl derivatives 16 and 17 induce apoptosis in both HeLa and MCF‐7 cells. In HeLa cells, activation of caspase‐8, ‐9, and ‐3 suggests the involvement of both intrinsic and extrinsic pathways. In contrast, in MCF‐7 cells, the increased expression of p53 and p21, together with PARP cleavage, suggests a p53‐dependent apoptotic response. Derivatives 16 and 17 emerged as promising Eg5 inhibitors from docking studies, but their poor aqueous solubility (0.2–0.7 µM), despite high biological stability, highlights the need for formulation strategies to improve drug‐like properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
- Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm, Sweden.
- Trustlife Laboratories, Drug Research & Development Center, Istanbul, Turkey.
- Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.
- Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Turkey.
- Department of Pharmacy, Pharmaceutical Sciences, University of Bari "Aldo Moro", Bari, Italy.
ORCID-Profile: Stamatia Vassiliou, Ivana Cacciatore
Förderung
- Italian Ministry of Research
Zitieren
APA
Panagoulias, K., Kim, W., Ozdemir, M., Turan, B., Mardinoglu, A., Turkez, H., Trisciuzzi, D., Nicolotti, O., Di Stefano, A., Vassiliou, S., & Cacciatore, I. (2026). Development of Styryl‐Modified 3,4‐Dihydropyrimidin‐2(1 H )‐ones as Potential Antitumor Agents. ChemMedChem, 21(7). https://doi.org/10.1002/cmdc.202501073
Vancouver
Panagoulias K, Kim W, Ozdemir M, Turan B, Mardinoglu A, Turkez H, et al. Development of Styryl‐Modified 3,4‐Dihydropyrimidin‐2(1 H )‐ones as Potential Antitumor Agents. ChemMedChem. 2026;21(7). doi:10.1002/cmdc.202501073
BibTeX
@article{Panagoulias2026,
author = {Panagoulias, Konstantinos and Kim, Woonghee and Ozdemir, Murat and Turan, Busra and Mardinoglu, Adil and Turkez, Hasan and Trisciuzzi, Daniela and Nicolotti, Orazio and Di Stefano, Antonio and Vassiliou, Stamatia and Cacciatore, Ivana},
title = {Development of Styryl‐Modified 3,4‐Dihydropyrimidin‐2(1 H )‐ones as Potential Antitumor Agents},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {7},
doi = {10.1002/cmdc.202501073}
}
EUVIMED